These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29594983)

  • 1. Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.
    Olson KE; Bade AN; Namminga KL; Potash MJ; Mosley RL; Poluektova LY; Volsky DJ; Gendelman HE
    J Neurovirol; 2018 Aug; 24(4):398-410. PubMed ID: 29594983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of NXP031 in the MPTP-induced Parkinson's disease model.
    Song MK; Lee JH; Kim J; Kim JH; Hwang S; Kim YS; Kim YJ
    Neurosci Lett; 2021 Jan; 740():135425. PubMed ID: 33075422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease.
    Dutta D; Kundu M; Mondal S; Roy A; Ruehl S; Hall DA; Pahan K
    Neurobiol Dis; 2019 Dec; 132():104575. PubMed ID: 31445159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.
    Yang W; Hao W; Meng Z; Ding S; Li X; Zhang T; Huang W; Xu L; Zhang Y; Yang J; Gu X
    Mol Neurobiol; 2021 Feb; 58(2):603-616. PubMed ID: 32997292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.
    Son HJ; Lee JA; Shin N; Choi JH; Seo JW; Chi DY; Lee CS; Kim EM; Choe H; Hwang O
    Br J Pharmacol; 2012 Apr; 165(7):2213-27. PubMed ID: 21951056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
    Bezard E; Jaber M; Gonon F; Boireau A; Bloch B; Gross CE
    Eur J Neurosci; 2000 Aug; 12(8):2892-900. PubMed ID: 10971632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
    Ghosh A; Roy A; Matras J; Brahmachari S; Gendelman HE; Pahan K
    J Neurosci; 2009 Oct; 29(43):13543-56. PubMed ID: 19864567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
    Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
    Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.
    Wang XH; Lu G; Hu X; Tsang KS; Kwong WH; Wu FX; Meng HW; Jiang S; Liu SW; Ng HK; Poon WS
    BMC Neurosci; 2012 Nov; 13():142. PubMed ID: 23151254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
    Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
    J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
    Tristão FS; Amar M; Latrous I; Del-Bel EA; Prediger RD; Raisman-Vozari R
    Neurotox Res; 2014 Jan; 25(1):24-32. PubMed ID: 23690159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
    Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y
    Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
    Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway.
    Castro-Caldas M; Carvalho AN; Rodrigues E; Henderson C; Wolf CR; Gama MJ
    Mol Neurobiol; 2012 Jun; 45(3):466-77. PubMed ID: 22539231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.
    Boska MD; Lewis TB; Destache CJ; Benner EJ; Nelson JA; Uberti M; Mosley RL; Gendelman HE
    J Neurosci; 2005 Feb; 25(7):1691-700. PubMed ID: 15716405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.